Albert Bourla, Chairman and CEO of Pfizer Inc., filed a Form 4 with the SEC on September 1, 2026, disclosing the acquisition of 21 Phantom Stock Units under the company's Nonfunded Deferred Compensation and Supplemental Savings Plan, with a transaction date of August 31, 2026.

Key Highlights

  • Reporting Person: Albert Bourla, identified as Chairman and CEO and a Director of Pfizer Inc. (NYSE:PFE)
  • Security Acquired: 21 Phantom Stock Units (SSP), each representing one phantom share of common stock, acquired on 08/31/2026
  • Price Per Unit: $28.46, as reported in the filing
  • Total Holdings After Transaction: 784,012 Phantom Stock Units beneficially owned directly following the reported transaction
  • Settlement Terms: Units are settled in cash following the reporting person's separation from service, according to the filing
  • Plan Source: Units were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan

Bourla Acquires Phantom Stock Units Under Pfizer Deferred Compensation Plan

According to the Form 4 filed with the SEC, Albert Bourla, serving as both Chairman and Chief Executive Officer of Pfizer Inc., acquired 21 Phantom Stock Units with a transaction code of "A" (acquired) on August 31, 2026. The filing was signed on September 1, 2026, by Shanice A. Reid by power of attorney for Albert Bourla. The issuer is identified as PFIZER INC with ticker symbol PFE, listed on the NYSE.

The filing classifies the Phantom Stock Units as derivative securities under Table II. Each unit, according to the filing's explanation of responses, "represents one phantom share of common stock." The units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. The filing states that the units "are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time." The price per unit is listed as $28.46, and ownership is reported as direct.

Following the reported transaction, Bourla's total beneficial ownership of Phantom Stock Units stands at 784,012, as disclosed in the filing. No transactions in non-derivative securities (Table I) were reported in this filing. No expiration date or exercisable date is listed for these units, consistent with the cash-settlement terms described in the filing's footnotes.

What Was Disclosed

The filing reports the acquisition of 21 Phantom Stock Units by Pfizer's Chairman and CEO on August 31, 2026, under the company's deferred compensation plan, at $28.46 per unit, bringing total direct beneficial ownership of such units to 784,012.